Programmed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study

Programmed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study

Treatment options for non-small cell lung cancer (NSCLC) are evolving, given recent and expected approvals of immune checkpoint inhibitors (ICIs) targeting programmed cell death-(ligand) 1 (PD-1/PD-L1). We retrospectively evaluated outcomes among patients with resected stage IB-IIIA NSCLC tumors exp...

Full description

Saved in:
Bibliographic Details
Main Authors: Parneet K. Cheema, Iqra Syed, Femida Gwadry-Sridhar, Muhammad Rakibuz-Zaman, Robin Sachdeva, Alec Pencz, Luna Zhan, Katrina Hueniken, Devalben Patel, Karmugi Balaratnam, Khaleeq Khan, Benjamin Grant, Brandon S. Sheffield, M. Elizabeth O. Locke, Daniel Moldaver, Mary Kate Shanahan, Geoffrey Liu, M. Sara Kuruvilla
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Current Oncology
Subjects:
non-small cell lung cancer
early stage
real world
programmed cell death-ligand 1
prevalence
recurrence
Online Access:https://www.mdpi.com/1718-7729/31/11/497
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/31/11/497

Similar Items